Latest Posts

Partnering to unlock the true potential of cannabis in medical care

AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More

Partex-NV-announces-collaboration-with-Althea-DRF-Lifesciences

28

Mar 24

Partex NV announces collaboration with Althea DRF Lifesciences to provide comprehensive end-to-end services to accelerate drug discovery and development

featured, Press release 2024

Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF...

Partex-Group-presents-results-from-a-pilot-project-with-AIO

18

Mar 24

Innovative AI technology in oncology: Partex Group presents results from a pilot project

featured, Press release 2024

During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the...

Innoplexus wins Horizon Interactive Gold Award for Curia App

Author name: Gunjan Bhardwaj

Gunjan Bhardwaj is the founder and CEO of Innoplexus, a leader in AI and analytics as a service for life science industries. With a background at Boston Consulting Group and Ernst & Young, he bridges the worlds of AI, consulting, and life science to drive innovation.

Why pharma companies need to upgrade their intelligence

Life Science / By Gunjan Bhardwaj

How Blockchain can improve the Pharma manufacturing supply chain

Life Science / By Gunjan Bhardwaj

Drug prices are too expensive: Here’s how technology can fix that

Life Science / By Gunjan Bhardwaj

Five use cases for Blockchain in Pharma

Life Science / By Gunjan Bhardwaj

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	The cookies are used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is used to store whether or not a user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

Latest Posts

Partnering to unlock the true potential of cannabis in medical care

28

Partex NV announces collaboration with Althea DRF Lifesciences to provide comprehensive end-to-end services to accelerate drug discovery and development

18

Innovative AI technology in oncology: Partex Group presents results from a pilot project

Author name: Gunjan Bhardwaj

Why pharma companies need to upgrade their intelligence

How Blockchain can improve the Pharma manufacturing supply chain

Drug prices are too expensive: Here’s how technology can fix that

Five use cases for Blockchain in Pharma

Partnering to unlock the true potential of cannabis in medical care

Partnering to make 100,000s COVID-19 publications searchable

Machine learning as an indispensable tool for Biopharma

Precision medicine and the discovery of biomarkers

Partex NV announces collaboration with Althea DRF Lifesciences to provide comprehensive end-to-end services to accelerate drug discovery and development

Innovative AI technology in oncology: Partex Group presents results from a pilot project

Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment for Out-Licensing

Innoplexus and AIO Studien gGmbH are jointly announcing the start of a pilot project as part of the AIO data hub initiative

WHO WE ARE

WHAT WE OFFER

HOW WE WORK

WHY US

Updates

Frankfurt (Germany)

Pune (India)

Iselin (USA)

Cham (Switzerland)